WT1 and thymoma: A WT-1 peptide vaccine was evaluated in a phase II trial in patients with relapsed/refractory, HLA-A*24:02 positive thymoma, or TC expressing Wilms’ tumor-1 (WT-1) protein, which was found to be overexpressed in TETs (thymomas: 80%; TCs 84.6%) [68].